PIK3CA and breast carcinoma: Given that their clinical efficacy and tolerability were confirmed in HER2-negative breast cancer22, AKT inhibitors, such as ipatasertib, may be evaluated in combination with anti-HER2 therapies targeting patients with HER2+ breast cancer with constitutive activation of the PI3K/AKT/mTOR pathway.